Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions

(2020) Shiying Shao et al.   PHARMACOLOGY & THERAPEUTICS

Glucose transport in lymphocytes

(2020) Florian Lang et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells

(2020) Laween Uthman et al.   CARDIOVASCULAR DRUGS AND THERAPY

Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?

(2020) Niki Katsiki et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome

(2019) Yochai Birnbaum et al.   BASIC RESEARCH IN CARDIOLOGY

Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells

(2018) Chenke Xu et al.   BIOCHEMICAL PHARMACOLOGY

Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes

(2018) Yochai Birnbaum et al.   CARDIOVASCULAR DRUGS AND THERAPY

Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection

(2018) Katarina Tomovic et al.   MEDICINAL RESEARCH REVIEWS

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH

(2018) Kumiko Shiba et al.   Scientific Reports

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms

(2018) Sarah J. Mancini et al.   Scientific Reports

Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys

(2018) Habib Yaribeygi et al.   DRUG DISCOVERY TODAY

The anti-inflammatory effect of Sonchus oleraceus aqueous extract on lipopolysaccharide stimulated RAW 264.7 cells and mice

(2017) Qi Li et al.   PHARMACEUTICAL BIOLOGY

Dipeptidyl Peptidase‐4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation

(2017) Taichi Ikedo et al.   Journal of the American Heart Association

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

(2017) Liang Xu et al.   EBioMedicine

Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system

(2016) C. Klemann et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects

(2016) André J. Scheen   Expert Opinion on Drug Metabolism & Toxicology

TNF and ROS Crosstalk in Inflammation

(2016) Heiko Blaser et al.   TRENDS IN CELL BIOLOGY

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

(2016) Teruo Jojima et al.   Diabetology & Metabolic Syndrome

DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation

(2015) Takanori Shinjo et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors

(2015) Kohichi Kawahara et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control

(2015) A.J. Scheen et al.   DIABETES & METABOLISM

The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms

(2015) Hwan-Jin Hwang et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes

(2014) Nathalie Esser et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease

(2014) Nathalie Esser et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The Role of SGLT1 and GLUT2 in Intestinal Glucose Transport and Sensing

(2014) Pia V. Röder et al.   PLoS One

Regional distribution of SGLT activity in rat brain in vivo

(2012) Amy S. Yu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral Inflammation

(2012) Jixin Zhong et al.   DIABETES

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Inflammatory links between obesity and metabolic disease

(2011) Carey N. Lumeng et al.   JOURNAL OF CLINICAL INVESTIGATION

Systematic validation of specific phenotypic markers for in vitro polarized human macrophages

(2011) C.A. Ambarus et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Harmonizing the Metabolic Syndrome

(2009) K.G.M.M. Alberti et al.   CIRCULATION

DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes

(2007) Carolyn et al.   Frontiers in Bioscience-Landmark